|
The effect of combined treatment with anti-IL-9 and anti-IL-5 or their isotype control on cell profiles in differenttissue compartments |
||||
| IsC of anti-IL9 + IsC of anti-IL-5 |
Anti-IL-9 + Anti-IL-5 |
Anti-IL-5 + IsC of anti-IL-9 |
Anti-IL-9 + IsC of anti-IL-5 |
|
|
|
||||
| Bone marrow eosinophils(%): |
19.3 ± 2.5 |
3.6 ± 0.6** |
3.6 ± 0.7** |
18.4 ± 2.2 |
| Immature eos. (%) |
13.4 ± 2.1 |
2.3 ± 0.4** |
2.3 ± 0.4** |
14.8 ± 2.1 |
| Mature eos. (%) |
5.9 ± 0.6 |
1.2 ± 0.3** |
1.4 ± 0.5** |
3.7 ± 0.4* |
|
|
||||
| Blood cells (total no., ×106/ml): |
1.9 ± 0.2 |
1.5 ± 0.6 |
1.3 ± 0.3 |
1.7 ± 0.2 |
| Neutrophils (×106/ml) |
0.7 ± 0.1 |
0.8 ± 0.3 |
0.56 ± 0.1 |
0.7 ± 0.1 |
| Eosinophils (×106/ml) |
0.3 ± 0.1 |
0.1 ± 0.03* |
0.1 ± 0.02* |
0.3 ± 0.04 |
| Monocytes (×106/ml) |
0.3 ± 0.04 |
0.2 ± 0.04 |
0.2 ± 0.1 |
0.2 ± 0.03 |
| Lymphocytes (×106/ml) |
0.5 ± 0.1 |
0.4 ± 0.2 |
0.5 ± 0.1 |
0.5 ± 0.1 |
|
|
||||
| BAL cells (total no., ×104/ml): |
109.3 ± 1.9 |
44.5 ± 7.6 |
45.9 ± 3.3 |
92.4 ± 8.8 |
| Macrophages (×104/ml) |
18.9 ± 1.9 |
11.8 ± 1.0 |
11.7 ± 0.3 |
16.9 ± 3.4 |
| Neutrophils (×104/ml) |
5.4 ± 1.7 |
3.8 ± 0.7 |
4.6 ± 1.0 |
4.9 ± 1.2 |
| Eosinophils (×104/ml) |
67.9 ± 15.1 |
20.0 ± 6.3* |
18.8 ± 2.1* |
54.8 ± 6.0 |
| Lymphocytes (×104/ml) |
16.8 ± 3.2 |
8.5 ± 1.8 |
10.7 ± 1.2 |
15.5 ± 4.5 |
|
Balb/c mice sensitized to OVA were subjected to repeated allergen exposure (OVA; 100 μg i.n. on five consecutive days). Neutralizing anti-IL-9 (100 μg/animal i.p.) and anti-IL-5 (50 μg/animal i.p.) treatment or their isotype controls treatment, or single antibody in a combination with respective isotype control, were given before the allergen exposure. BAL was performed 24 hours after the last allergen exposure. Data represent mean ± SEM (n = 5 per point). * p < 0.05 and ** p < 0.01 compared with the isotype control antibodies treated group. IsC – isotype control. | ||||
Sitkauskiene et al. Respiratory Research 2005 6:33 doi:10.1186/1465-9921-6-33 |
||||